Cellular and molecular mechanisms of action of bisphosphonates, Cancer, vol.20, issue.52, pp.2961-2978, 2000. ,
DOI : 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis, American Journal of Clinical Oncology, vol.25, pp.3-9, 2002. ,
DOI : 10.1097/00000421-200212001-00002
Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis, J Lipid Res, vol.33, pp.1657-1663, 1992. ,
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase, Archives of Biochemistry and Biophysics, vol.373, issue.1, pp.231-241, 2000. ,
DOI : 10.1006/abbi.1999.1502
Identification of a Bisphosphonate That Inhibits Isopentenyl Diphosphate Isomerase and Farnesyl Diphosphate Synthase, Biochemical and Biophysical Research Communications, vol.290, issue.2, pp.869-873108, 1999. ,
DOI : 10.1006/bbrc.2001.6289
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs, Mol Pharmacol, vol.56, pp.131-140, 1999. ,
Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras, Journal of Bone and Mineral Research, vol.8, issue.Suppl 4, pp.581-589, 1998. ,
DOI : 10.1359/jbmr.1998.13.4.581
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway, Cellular Signalling, vol.15, issue.7, pp.719-727, 2003. ,
DOI : 10.1016/S0898-6568(03)00007-X
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, Proceedings of the National Academy of Sciences, vol.14, issue.5, pp.133-138, 1999. ,
DOI : 10.1023/A:1012157212793
Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho, Cancer Res, vol.62, pp.6015-6020, 2002. ,
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects, British Journal of Cancer, vol.88, issue.10 ,
DOI : 10.1038/sj.bjc.6600925
Protein Geranylgeranylation Is Required for Osteoclast Formation, Function, and Survival: Inhibition by Bisphosphonates and GGTI-298, Journal of Bone and Mineral Research, vol.108, issue.8, pp.1467-1476, 2000. ,
DOI : 10.1359/jbmr.2000.15.8.1467
Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogencontaining bisphosphonates on osteoclast precursors, Bone, vol.30, issue.1, pp.64-70, 2002. ,
DOI : 10.1016/S8756-3282(01)00655-X
Nitrogen Containing Bisphosphonates Induce Apoptosis and Inhibit the Mevalonate Pathway, Impairing Ras Membrane Localization in Prostate Cancer Cells, The Journal of Urology, vol.170, issue.1, pp.246-252, 2003. ,
DOI : 10.1097/01.ju.0000070685.34760.5f
The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells, British Journal of Cancer, vol.90, issue.9, pp.1479-1486, 2002. ,
DOI : 10.1038/sj.bjc.6600297
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway, Cancer Res, vol.62, pp.2708-2714, 2002. ,
Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid, Seminars in Oncology, vol.29, issue.6 Suppl 21, pp.19-27, 2002. ,
DOI : 10.1053/sonc.2002.37418
Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.345, issue.13, pp.948-955, 2001. ,
DOI : 10.1056/NEJMoa010845
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases, Cancer Res, vol.60, pp.2949-2954, 2000. ,
Bisphosphonate treatment inhibits the growth of prostate cancer cells, Cancer Res, vol.61, pp.2602-2608, 2001. ,
Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes, Journal of Biological Chemistry, vol.270, issue.45 ,
DOI : 10.1074/jbc.270.45.26802
Platelet-derived Growth Factor Receptor Tyrosine Phosphorylation Requires Protein Geranylgeranylation but not Farnesylation, Journal of Biological Chemistry, vol.271, issue.44, pp.27402-27407, 1996. ,
DOI : 10.1074/jbc.271.44.27402
Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene, J Urol, vol.146, pp.881-886, 1991. ,
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, JNCI Journal of the National Cancer Institute, vol.82, issue.13, pp.1107-1112, 1990. ,
DOI : 10.1093/jnci/82.13.1107
Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells, The Journal of Nutritional Biochemistry, vol.14, issue.2, pp.111-119, 2003. ,
DOI : 10.1016/S0955-2863(02)00274-7
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer, Clin Cancer Res, vol.9, pp.295-306, 2003. ,
Novel Salvage Pathway Utilizing Farnesol and Geranylgeraniol for Protein Isoprenylation, Biochemical and Biophysical Research Communications, vol.237, issue.3, pp.483-487, 1997. ,
DOI : 10.1006/bbrc.1997.7145
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I, Mol Cancer Ther, vol.1, pp.747-758, 2002. ,
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase, Bioorganic & Medicinal Chemistry, vol.6, issue.6, pp.687-694, 1998. ,
DOI : 10.1016/S0968-0896(98)00034-0
Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis, Lipids, vol.277, issue.7, pp.751-759, 2003. ,
DOI : 10.1007/s11745-003-1123-8
RhoA Prenylation Is Required for Promotion of Cell Growth and Transformation and Cytoskeleton Organization but Not for Induction of Serum Response Element Transcription, Journal of Biological Chemistry, vol.275, issue.40, pp.31001-31008, 2000. ,
DOI : 10.1074/jbc.M005264200
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates, J Pharmacol Exp Ther, vol.296, pp.235-242, 2001. ,
Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway, Endocrinology, vol.141, issue.12, pp.4793-4796, 2000. ,
DOI : 10.1210/endo.141.12.7921